Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain
Parada L., Marstein J. P., Danilov A. B.
Pain Management
Vol.6, Issue5, P. 445-454
Опубликовано: 2016
Тип ресурса: Статья
Аннотация:
AIM: To assess the safety of lornoxicam with particular focus on gastrointestinal (GI) events.METHODS: Data on adverse drug reactions (ADRs) were pooled from 60 comparative studies of lornoxicam.RESULTS: A total of 6420 patients received lornoxicam, 1192 received placebo and 3770 received a comparator analgesic. ADRs were reported by 21[%] of lornoxicam-treated patients, with GI events the most frequent (14 vs 8[%] with placebo). Across 15 studies that compared lornoxicam (n = 1287) with another NSAID (n = 1010), there was a reduced risk of a GI ADR with lornoxicam (0.78 [95[%] CI: 0.64-0.96]; p = 0.017).CONCLUSION: Lornoxicam was well tolerated with the type of GI events observed consistent with the known safety profile of NSAIDs.
Ключевые слова:
acute pain; COX inhibitors; gastrointestinal toxicity; lornoxicam; NSAIDs; oxicams; rheumatic pain
lornoxicam; piroxicam; prostaglandin synthase inhibitor; adult; analogs and derivatives; chemically induced; clinical trial (topic); complication; female; gastrointestinal disease; human; male; middle aged; pain; rheumatoid arthritis; treatment outcome; Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pain; Piroxicam; Treatment Outcome
Язык текста: Английский
ISSN: 1758-1877
Parada L.
Marstein J. P.
Danilov A. B. Andrej Borisovich 1962-
Парада Л.
Марстеин Й. П.
Данилов А. Б. Андрей Борисович 1962-
Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain
Текст визуальный непосредственный
Pain Management
Vol.6, Issue5 P. 445-454
2016
Статья
acute pain COX inhibitors gastrointestinal toxicity lornoxicam NSAIDs oxicams rheumatic pain
lornoxicam piroxicam prostaglandin synthase inhibitor adult analogs and derivatives chemically induced clinical trial (topic) complication female gastrointestinal disease human male middle aged pain rheumatoid arthritis treatment outcome Adult Arthritis, Rheumatoid Clinical Trials as Topic Cyclooxygenase Inhibitors Female Gastrointestinal Diseases Humans Male Middle Aged Pain Piroxicam Treatment Outcome
AIM: To assess the safety of lornoxicam with particular focus on gastrointestinal (GI) events.METHODS: Data on adverse drug reactions (ADRs) were pooled from 60 comparative studies of lornoxicam.RESULTS: A total of 6420 patients received lornoxicam, 1192 received placebo and 3770 received a comparator analgesic. ADRs were reported by 21[%] of lornoxicam-treated patients, with GI events the most frequent (14 vs 8[%] with placebo). Across 15 studies that compared lornoxicam (n = 1287) with another NSAID (n = 1010), there was a reduced risk of a GI ADR with lornoxicam (0.78 [95[%] CI: 0.64-0.96]; p = 0.017).CONCLUSION: Lornoxicam was well tolerated with the type of GI events observed consistent with the known safety profile of NSAIDs.